Hydrocortisone plus fludrocortisone for adults with septic shock.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Septic shock is characterized by dysregulation of the host response to infection, with circulatory, cellular, and metabolic abnormalities. We hypothesized that therapy with hydrocortisone plus fludrocortisone or with drotrecogin alfa (activated), which can modulate the host response, would improve the clinical outcomes of patients with septic shock. METHODS: In this multicenter, double-blind, randomized trial with a 2-by-2 factorial design, we evaluated the effect of hydrocortisone-plus-fludrocortisone therapy, drotrecogin alfa (activated), the combination of the three drugs, or their respective placebos. The primary outcome was 90-day all-cause mortality. Secondary outcomes included mortality at intensive care unit (ICU) discharge and hospital discharge and at day 28 and day 180 and the number of days alive and free of vasopressors, mechanical ventilation, or organ failure. After drotrecogin alfa (activated) was withdrawn from the market, the trial continued with a two-group parallel design. The analysis compared patients who received hydrocortisone plus fludrocortisone with those who did not (placebo group). RESULTS: Among the 1241 patients included in the trial, the 90-day mortality was 43.0% (264 of 614 patients) in the hydrocortisone-plus-fludrocortisone group and 49.1% (308 of 627 patients) in the placebo group (P=0.03). The relative risk of death in the hydrocortisone-plus-fludrocortisone group was 0.88 (95% confidence interval, 0.78 to 0.99). Mortality was significantly lower in the hydrocortisone-plus-fludrocortisone group than in the placebo group at ICU discharge (35.4% vs. 41.0%, P=0.04), hospital discharge (39.0% vs. 45.3%, P=0.02), and day 180 (46.6% vs. 52.5%, P=0.04) but not at day 28 (33.7% and 38.9%, respectively; P=0.06). The number of vasopressor-free days to day 28 was significantly higher in the hydrocortisone-plus-fludrocortisone group than in the placebo group (17 vs. 15 days, P<0.001), as was the number of organ-failure-free days (14 vs. 12 days, P=0.003). The number of ventilator-free days was similar in the two groups (11 days in the hydrocortisone-plus-fludrocortisone group and 10 in the placebo group, P=0.07). The rate of serious adverse events did not differ significantly between the two groups, but hyperglycemia was more common in hydrocortisone-plus-fludrocortisone group. CONCLUSIONS: In this trial involving patients with septic shock, 90-day all-cause mortality was lower among those who received hydrocortisone plus fludrocortisone than among those who received placebo. (Funded by Programme Hospitalier de Recherche Clinique 2007 of the French Ministry of Social Affairs and Health; APROCCHSS ClinicalTrials.gov number, NCT00625209 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the ADRENAL [479] study, hydrocortisone was administered for a maximum of seven days or until ICU discharge or death; in APROCCHSS [478] hydrocortisone was administered for seven days; in VANISH [354] 200 mg of hydrocortisone was administered daily for 5 days and then tapered over further 6 days.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
In the citing paper
“In APROCCHSS [478] the dose of vasopressor was ≥ 0.25 µg/kg/min or ≥ 1 mg/h of norepinephrine or epinephrine, or any other vasopressor for at least 6 h to maintain a MAP ≥ 65 mmHg.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
In the citing paper
“Since then, three large RCTs have been published [354, 478, 479].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Self-citationDellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0934-2 · Cited by 6,772
Self-citationSurviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Self-citationVincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Annane, D. (2002) · JAMA · doi:10.1001/jama.288.7.862 · Cited by 3,087
Self-citationShankar-Hari, M., Phillips, G. S., Levy, M. L., Seymour, C. W., Liu, V. X., Deutschman, C. S., Angus, D. C., Rubenfeld, G. D., Singer, M., & for the Sepsis Definitions Task Force (2016) · JAMA · doi:10.1001/jama.2016.0289 · Cited by 2,424
Hydrocortisone Therapy for Patients with Septic Shock
Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., Weiss, Y. G., Benbenishty, J., Kalenka, A., Forst, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa071366 · Cited by 2,132
Self-citationAnnane, D., Bellissant, E., & Cavaillon, J.-M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17667-8 · Cited by 1,213
Self-citationAnnane, D., Vignon, P., Renault, A., Bollaert, P.-E., Charpentier, C., Martin, C., Troché, G., Ricard, J.-D., Nitenberg, G., Papazian, L., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61344-0 · Cited by 567
Self-citationCognitive decline after sepsis.
Annane, D., & Sharshar, T. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70246-2 · Cited by 290
Self-citation
Research works printed but not linked: 1
- Guide “100 recommandations pour la surveillance et la préventions des infections nosocomiales.” Bulletin Epidémiologique Hebdomadaire. No. 48. November 30 1992 (http://invs.santepubliquefrance.fr/beh/1992/48/index.html).
Cited by
Items 101–200 of 968
Low-Dose Corticosteroids for Critically Ill Adults With Severe Pulmonary Infections: A Review
Pirracchio, R., Venkatesh, B., & Legrand, M. M. (2024) · JAMA · doi:10.1001/jama.2024.6096 · Cited by 76
Sanchez-Pinto, L. N., Stroup, E. K., Pendergrast, T. R., Pinto, N. P., & Luo, Y. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.9271 · Cited by 78
den Berghe, G. V., Téblick, A., Langouche, L., & Gunst, J. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104284 · Cited by 76
Ltaief, Z., Ben‐Hamouda, N., Rancati, V., Gunga, Z., Marcucci, C., Kirsch, M. E. W., & Liaudet, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216407 · Cited by 86
Timing of vasoactive agents and corticosteroid initiation in septic shock
Ammar, M. A., Ammar, A. A., Wieruszewski, P. M., Bissell, B. D., Long, M. T., Albert, L., Khanna, A. K., & Sacha, G. L. (2022) · Annals of Intensive Care · doi:10.1186/s13613-022-01021-9 · Cited by 78
“study and the Activated Protein C and Corticosteroids for Human Septic Shock (APROCCHSS) trial reported a significant benefit in all-cause mortality in septic shock patients who received a low-dose corticosteroid regimen compared to placebo [64, 67].”
BackgroundResultPirracchio, R., Hubbard, A., Sprung, C. L., Chevret, S., Annane, D., & Collaborators, R. R. O. C. R. O. S. S. (. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.29050 · Cited by 74
Self-citationThe initial resuscitation of septic shock
Cinel, I., Kasapoglu, U. S., Gul, F., & Dellinger, R. P. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.02.004 · Cited by 69
The Central Role of the Inflammatory Response in Understanding the Heterogeneity of Sepsis-3
Ding, R., Meng, Y., & Ma, X. (2018) · BioMed Research International · doi:10.1155/2018/5086516 · Cited by 71
“fludrocortisone was reported to significantly reduce 90-day mortality in patients with septic shock [62].”
BackgroundChen, J., & Wei, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.718089 · Cited by 80
Sartelli, M., Tascini, C., Coccolini, F., Dellai, F., Ansaloni, L., Antonelli, M. M., Bartoletti, M., Bassetti, M., Boncagni, F., Carlini, M., et al. (2024) · World Journal of Emergency Surgery · doi:10.1186/s13017-024-00551-w · Cited by 77
“Although these studies failed to show a reduction in 28-day mortality, corticosteroids provided significantly faster resolution of shock and more rapid weaning from mechanical ventilation without increasing the infection rate [63, 64].”
BackgroundBlood Purification Techniques for Sepsis and Septic AKI
Girardot, T., Schneider, A. G., & Rimmele, T. R. (2019) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2019.06.010 · Cited by 65
Critical Illness–induced Corticosteroid Insufficiency: What It Is Not and What It Could Be
Téblick, A., Gunst, J., & den Berghe, G. V. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac201 · Cited by 71
Management of Sepsis in Patients With Cirrhosis: Current Evidence and Practical Approach
Simonetto, D. A., Serafim, L. P., de Moraes, A. G., Gajic, O., & Kamath, P. S. (2018) · Hepatology · doi:10.1002/hep.30412 · Cited by 64
“A recent large, multicenter trial showed that hydrocortisone alone does not reduce mortality compared to placebo,(61) whereas another recent study demonstrated that combination hydrocortisone plus fludrocortisone may improve 90-day survival in patients with septic shock.(62) Nonetheless, the effect of corticosteroid t…”
ResultDisease Mechanisms of Perioperative Organ Injury
Conrad, C., & Eltzschig, H. K. (2020) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000005191 · Cited by 72
Evaluating Vitamin C in Septic Shock: A Randomized Controlled Trial of Vitamin C Monotherapy*
Wacker, D. A., Burton, S. L., Berger, J. P., Hegg, A. J., Heisdorffer, J., Wang, Q., Medcraft, E. J., & Reilkoff, R. A. (2022) · Critical Care Medicine · doi:10.1097/ccm.0000000000005427 · Cited by 63
Hajjar, L. A., Zambolim, C. M., Belletti, A., de Almeida, J. P., Gordon, A. C., Oliveira, G., Park, C. H. L., Fukushima, J. T., Rizk, S. I., Szeles, T. F., et al. (2019) · Critical Care Medicine · doi:10.1097/ccm.0000000000004023 · Cited by 67
Management of Sepsis and Septic Shock: What Have We Learned in the Last Two Decades?
Kamath, S., Altaq, H. H., & Abdo, T. (2023) · Microorganisms · doi:10.3390/microorganisms11092231 · Cited by 69
“The status quo was shaken up a little bit a decade after the 2008 SSC guidelines with the concurrent publication of ADRENAL and APROCCHSS in 2018, the two largest randomized controlled trials examining the effect of steroids in septic shock [171,172].”
Heming, N., Renault, A., Kuperminc, E., Brun‐Buisson, C., Mégarbane, B., Quenot, J., Siami, S., Cariou, A., Forceville, X., Schwebel, C., et al. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00430-7 · Cited by 62
Self-citationAsehnoune, K., Moal, C. L., Lebuffe, G., Penndu, M. L., Josse, N. C., Boisson, M., Lescot, T., Faucher, M., Jaber, S., Godet, T., et al. (2021) · BMJ · doi:10.1136/bmj.n1162 · Cited by 61
Self-citationNecrotizing Fasciitis: Pillaging the Acute Phase Response
Hysong, A. A., Posey, S. L., Blum, D. M., Benvenuti, M. A., Benvenuti, T. A., Johnson, S. R., An, T. J., Devin, J. K., Obremskey, W. T., Martus, J. E., et al. (2020) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.19.00591 · Cited by 69
Imbalance of Circulating Innate Lymphoid Cell Subpopulations in Patients With Septic Shock
Carvelli, J., Pipéroglou, C., Bourenne, J., Farnarier, C., Banzet, N., Demerle, C., Gainnier, M., & Vely, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02179 · Cited by 58
“The proportion of ILC1s within total ILCs followed the same pattern: 66% [32–96] of circulating ILC1s in the sepsis group, 64% [27–83] in the ICU controls, and 30% [13-71] in the healthy controls (p < 0.”
BackgroundAntimicrobial Treatment Duration in Sepsis and Serious Infections
Busch, L. M., & Kadri, S. S. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa247 · Cited by 64
Population enrichment for critical care trials: phenotypes and differential outcomes
Shankar‐Hari, M., & Rubenfeld, G. D. (2019) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000641 · Cited by 61
“This is illustrated in two recent corticosteroid trials in septic shock, where the trial with higher mortality showed better risk reduction [52,53].”
ResultDysregulated dendritic cells in sepsis: functional impairment and regulated cell death
Zheng, L., Duan, Y., He, P.-Y., Wu, M., Wei, S.-T., Du, X., Yao, R.-Q., & Yao, Y. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00602-9 · Cited by 58
Barnes, T. J., Hockstein, M. A., & Jabaley, C. S. (2020) · SAGE Open Medicine · doi:10.1177/2050312120935466 · Cited by 54
Lesur, O., Delile, E., Asfar, P., & Radermacher, P. (2018) · Annals of Intensive Care · doi:10.1186/s13613-018-0449-8 · Cited by 56
The role of thromboinflammation in acute kidney injury among patients with septic coagulopathy
Iba, T., Helms, J., Maier, C. L., Levi, M. M., Scărlătescu, E., & Levy, J. H. (2024) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2024.02.006 · Cited by 56
Anterior pituitary function in critical illness
Téblick, A., Langouche, L., & Van den Berghe, G. (2019) · Endocrine Connections · doi:10.1530/ec-19-0318 · Cited by 52
Corticosteroids for Treating Sepsis in Adult Patients: A Systematic Review and Meta-Analysis
Liang, H., Song, H., Zhai, R., Song, G., Li, H., Ding, X., Kan, Q., & Sun, T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.709155 · Cited by 62
“Eleven RCTs (21–23, 25, 27, 28, 34, 35, 41, 51, 56) reported ICU mortality, seven studies (21–23, 34, 35, 41, 56) of which reported the corticosteroids dose was 200 mg/day or 50 mg every 6 h; only one (21) study showed that corticosteroids may be associated with the lower ICU mortality.”
BackgroundInfluentialPaik, S., Choe, J. H., Choi, G.-E., Kim, J.-E., Kim, J., Song, G., & Jo, E. (2019) · Scientific Reports · doi:10.1038/s41598-019-40690-8 · Cited by 53
Tsai, M., Yang, K., Chan, M.-C., Kao, K., Wang, H., Perng, W., Wu, C., Liang, S., Fang, W., Tsai, J., et al. (2020) · Annals of Intensive Care · doi:10.1186/s13613-020-0642-4 · Cited by 53
Etomidate, Adrenal Insufficiency and Mortality Associated With Severity of Illness: A Meta-Analysis
Albert, S. G., & Sitaula, S. (2020) · Journal of Intensive Care Medicine · doi:10.1177/0885066620957596 · Cited by 51
“Also, clarification of the effect of etomidate may not be forthcoming, as more recent prospective trials of corticosteroids in septic shock have specifically excluded patients receiving etomidate.(30,31) Although there Figure 3.”
BackgroundLin, S., Lu, W., Wang, T., Wang, Y., Leng, X., Chi, L., Jin, P., & Bian, J. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2303395 · Cited by 59
“Notably, invasive mechanical ventilation insti-gates an elevation in intrathoracic pressure, inducing a concomitant reduction in venous return and mean arterial pressure, thereby fostering a milieu conducive to prerenal hypoperfusion and the subsequent onset of acute renal injury [27].”
BackgroundThe role of glucocorticoids as adjunctive treatment for sepsis in the modern era
Marik, P. E. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30265-0 · Cited by 50
Ascorbic Acid, Thiamine, and Steroids in Septic Shock: Propensity Matched Analysis
Sadaka, F. G., Grady, J., Organti, N. K., Donepudi, B., Korobey, M. J., Tannehill, D., & O’Brien, J. (2019) · Journal of Intensive Care Medicine · doi:10.1177/0885066619864541 · Cited by 49
“Review of steroids is beyond the scope of this article, but, in general, studies have generally shown steroids to improve clinical outcomes in SS, such as time to shock reversal, and ventilator-free days, with mixed results with respect to mortality.(18,19) The biologic basis of the drug combinations is based on the p…”
ResultIs Mortality a Useful Primary End Point for Critical Care Trials?
Veldhoen, R. A., Howes, D. W., & Maslove, D. M. (2019) · CHEST Journal · doi:10.1016/j.chest.2019.11.019 · Cited by 50
Teja, B., Berube, M., Pereira, T. V., Law, A. C., Schanock, C., Pang, B., Wunsch, H., Walkey, A. J., & Bosch, N. A. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202310-1785oc · Cited by 48
Hussain, H., Vutipongsatorn, K., Jiménez, B., & Antcliffe, D. B. (2022) · Metabolites · doi:10.3390/metabo12050376 · Cited by 51
Wu, S., Zhou, Q., Cai, Y., & Duan, X. (2023) · Renal Failure · doi:10.1080/0886022x.2023.2194436 · Cited by 47
The Burden of Sepsis and Septic Shock in the Intensive Care Unit
Via, L. L., Maniaci, A., Lentini, M., Cuttone, G., Ronsivalle, S., Tutino, S., Rubulotta, F. M., Nunnari, G., & Marıno, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196691 · Cited by 62
“Corticosteroids, specifically intravenous hydrocortisone (200 mg/day), are recommended in patients with septic shock unresponsive to fluids and vasopressors, as they may accelerate shock reversal and reduce vasopressor dependence, though survival benefit remains inconsistent [45,60].”
Chow, J. H., Abuelkasem, E., Sankova, S. K., Henderson, R. A., Mazzeffi, M. A., & Tanaka, K. A. (2019) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000004343 · Cited by 48
Pediatric sepsis biomarkers for prognostic and predictive enrichment
Wong, H. R. (2021) · Pediatric Research · doi:10.1038/s41390-021-01620-5 · Cited by 47
Jung, S., Lee, M., Baek, M. S., & Kim, W. (2022) · Critical Care · doi:10.1186/s13054-021-03872-3 · Cited by 48
“Low-dose corticosteroids have been shown to reverse septic shock [11, 12], although the use of hydrocortisone was not controlled in most of these trials [7, 9, 10].”
BackgroundEndothelial dysfunction: a therapeutic target in bacterial sepsis?
Vincent, J., İnce, C., & Pickkers, P. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1988928 · Cited by 48
“Annane and coworkers have demonstrated in several studies the beneficial effects of glucocorticosteroid therapy in sepsis [127,128].”
BackgroundThe Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024
Shime, N., Nakada, T.-A., Yatabe, T., Yamakawa, K., Aoki, Y., Inoue, S., Iba, T., Ogura, H., Kawai, Y., Kawaguchi, A., et al. (2025) · Journal of Intensive Care · doi:10.1186/s40560-025-00776-0 · Cited by 52
French intensive care unit organisation
Léone, M., Constantin, J., Dahyot‐Fizelier, C., Duracher, C., Joannès-Boyau, O., Langeron, O., Legrand, M. M., Mahjoub, Y., Mirek, S., Mrozek, S., et al. (2018) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2018.10.011 · Cited by 49
Self-citationMachine-learning-derived sepsis bundle of care
Kalimouttou, A., Lerner, I., Cheurfa, C., Jannot, A., & Pirracchio, R. (2022) · Intensive Care Medicine · doi:10.1007/s00134-022-06928-2 · Cited by 50
Tonnus, W., Gembardt, F., Latk, M., Parmentier, S. P., Hugo, C., Bornstein, S. R., & Linkermann, A. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0193-5 · Cited by 45
A Systematic Approach to the Treatment of Vasoplegia Based on Recent Advances in Pharmacotherapy
Ortoleva, J. P., & Cobey, F. C. (2018) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2018.11.025 · Cited by 44
Cancer Immunotherapy-Associated Hypophysitis
Castillero, F., Castillo, O., Jiménez, G. J., Fallas-Ramirez, J.-M., Álvarez, M. P. P., & Arrieta, O. G. (2019) · Future Oncology · doi:10.2217/fon-2019-0101 · Cited by 45
Management of liver failure in general intensive care unit
Paugam‐Burtz, C., Levesque, É., Louvet, A., Thabut, D., Amathieu, R., Bureau, C., Camus, C., Chanques, G., Faure, S., Ferrandière, M., et al. (2019) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2019.06.014 · Cited by 54
Self-citationRapoport, B. L., Cooksley, T., Johnson, D. B., Anderson, R., & Shannon, V. R. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1884067 · Cited by 47
“controversial with contradictory results from large randomized controlled trials [50,51].”
ResultSanthakumaran, S., Gordon, A. C., Prevost, A. T., O’Kane, C. M., McAuley, D. F., & Shankar‐Hari, M. (2019) · Critical Care · doi:10.1186/s13054-019-2446-1 · Cited by 44
Adrenergic Downregulation in Critical Care: Molecular Mechanisms and Therapeutic Evidence
Belletti, A., Landoni, G., Ломиворотов, В. В., Oriani, A., & Ajello, S. (2019) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2019.10.017 · Cited by 44
Assimakopoulos, S. F., Papadopoulou, I., Bantouna, D., de Lastic, A.-L., Rodi, M., Mouzaki, A., Gogos, C. A., Zolota, V., & Maroulis, I. (2021) · Shock · doi:10.1097/shk.0000000000001566 · Cited by 41
“A recent large randomized controlled trial enrolling 1,241 patients with septic shock, demonstrated a significant survival benefit in those treated with hydrocortisone-plus-fludrocortisone (4).”
BackgroundUse of IFNγ/IL10 Ratio for Stratification of Hydrocortisone Therapy in Patients With Septic Shock
König, R., Kolte, A., Ahlers, O., Oswald, M., Krauss, V., Roell, D., Sommerfeld, O., Dimοpoulos, G., Tsangaris, I., Antoniadou, E., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.607217 · Cited by 48
“Whereas, two French studies reported outcome benefit from a combination of hydrocortisone plus oral fludrocortisone (3, 4), the pan-European CORTICUS trial and the 5-country ADRENAL trial found no survival effect from hydrocortisone alone (2, 5).”
BackgroundMarik, P. E., & Farkas, J. D. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000003310 · Cited by 43
Lankadeva, Y. R., Shehabi, Y., Deane, A. M., Plummer, M. P., Bellomo, R., & May, C. N. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15363 · Cited by 42
“…can contribute to the sepsis-induced reduction in pressor responsiveness to adrenergic vasopressors (noradrenaline and phenylephrine) and non-adrenergic vasopressors (angiotensin II) reported in human and ovine sepsis (Annane et al., 1998, 2018; Lankadeva et al., 2015; Lankadeva, Ma, et al., 2019).”
BackgroundInfluentialCorticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm?
Martín‐Loeches, I., & Torres, A. (2021) · European Respiratory Review · doi:10.1183/16000617.0346-2020 · Cited by 46
Invasive Aspergillosis in the Intensive Care Unit
Townsend, L., & Martín‐Loeches, I. (2022) · Diagnostics · doi:10.3390/diagnostics12112712 · Cited by 43
“This latter at-risk population is likely to grow, given the use of corticosteroids in patients with septic shock requiring vasopressor therapy in ICU settings [21,22].”
Nguyen, M., Denimal, D., Dargent, A., Guinot, P., Duvillard, L., Quenot, J., & Bouhemad, B. (2018) · Shock · doi:10.1097/shk.0000000000001285 · Cited by 41
“Corticosteroids reduce time to shock reversal and might even improve survival in septic shock (34, 35).”
BackgroundSelf-citationManagement of pneumonia in intensive care
Morris, A. C. (2018) · Journal of Emergency and Critical Care Medicine · doi:10.21037/jeccm.2018.11.06 · Cited by 51
“With the exception of those developing vasopressor resistant septic shock (131), there appears to be no place for the use of steroids in the management of HAP and VAP.”
BackgroundLiang, B., Su, J., Shao, H., Chen, H., & Xie, B. (2023) · Critical Care · doi:10.1186/s13054-023-04392-y · Cited by 43
“Corticosteroids decrease vasopressor requirements in septic shock [47, 48], and the hemodynamic improvement may be due to corticosteroids [34].”
BackgroundSevere Community-Acquired Pneumonia
Cillóniz, C., Dominedò, C., Liapikou, A., & Torres, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11487-4 · Cited by 41
Corticosteroid-binding globulin (CBG): spatiotemporal distribution of cortisol in sepsis
Lee, J. H., Meyer, E. J., Nenke, M., Falhammar, H., & Torpy, D. J. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.01.002 · Cited by 43
Langouche, L., Téblick, A., Gunst, J., & den Berghe, G. V. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad021 · Cited by 47
Review: sepsis guidelines and core measure bundles
Desposito, L., & Bascara, C. J. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2388021 · Cited by 46
The glucocorticoid receptor and cortisol levels in pediatric septic shock
Alder, M. N., Opoka, A. M., & Wong, H. R. (2018) · Critical Care · doi:10.1186/s13054-018-2177-8 · Cited by 40
Vasoactive Agent Use in Septic Shock: Beyond First‐Line Recommendations
Sacha, G. L., Bauer, S. R., & Lat, I. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2220 · Cited by 43
Mentzelopoulos, S. D., Pappa, E., Malachias, S., Vrettou, C. S., Giannopoulos, A., Karlis, G., Adamos, G., Pantazopoulos, I. N., Megalou, A. J., Louvaris, Z., et al. (2022) · Resuscitation Plus · doi:10.1016/j.resplu.2022.100252 · Cited by 40
Kuperminc, E., Heming, N., Carlos, M., & Annane, D. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12093340 · Cited by 48
Self-citationWhite, K. C., Costa‐Pinto, R., Blank, S. P., Whebell, S. F., Quick, L., Luke, S., Attokaran, A. G., Garrett, P., Ramanan, M., Tabah, A., et al. (2025) · Critical Care · doi:10.1186/s13054-025-05401-y · Cited by 39
“…beneficial effect of hydrocortisone treatment, a finding that contrasts with results from larger randomized controlled trials such as APPROACHS and ADRENAL, which have suggested its beneficial effects regarding ICU length of stay, duration of shock, and duration of mechanical ventilation [33, 34].”
Biomarkers and Precision Medicine
Sarma, A. A., Calfee, C. S., & Ware, L. B. (2019) · Critical Care Clinics · doi:10.1016/j.ccc.2019.08.012 · Cited by 42
Dupuis, C., de Montmollin, É., Buetti, N., Goldgran-Tolédano, D., Reignier, J., Schwebel, C., Domitile, J., Neuville, M., Ursino, M., Siami, S., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255644 · Cited by 43
“In other clinical settings, studies reported beneficial effects of CS in septic shock [7, 8], and ARDS [9].”
BackgroundInfluentialSelf-citationAre Corticosteroids Beneficial for Sepsis and Septic Shock? Based on Pooling Analysis of 16 Studies
Yao, Y., Lin, L., Gu, H.-Y., Wu, J., Niu, Y., & Zhang, C. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00714 · Cited by 46
Кirov, М. Y., Владимирович, К. В., Николаевич, П. Д., Щеголев, А. В., Babaev, M. A., Belotserkovskiy, B. Z., Bykov, A. O., Gritsan, A. I., Кулабухов, В. В., Kulikov, A. V., et al. (2023) · Annals of critical care · doi:10.21320/1818-474x-2023-4-7-42 · Cited by 44
Cortisol, Stress, and Disease—Bidirectional Associations; Role for Corticosteroid-Binding Globulin?
Lee, J. H., Meyer, E. J., Nenke, M. A., Lightman, S. L., & Torpy, D. J. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae412 · Cited by 41
Vasopressin and its analogues in patients with septic shock: holy Grail or unfulfilled promise?
Lajoye, Q., Orieux, A., Boyer, A., Prével, R., & Jozwiak, M. (2025) · Critical Care · doi:10.1186/s13054-025-05540-2 · Cited by 41
“…was rare (1 patient out of 1,157) or unspecified in the two recent pivotal trials on the effects of corticosteroids in patients with septic shock [150, 151], we believe that the administration of vasopressin and corticosteroids should be considered in combination in patients with refractory…”
What is new and different in the 2021 Surviving Sepsis Campaign guidelines
Prescott, H. C., & Ostermann, M. (2023) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-023-01028-5 · Cited by 45
Butler, E., Møller, M. H., Cook, O., Granholm, A., Penketh, J., Rygård, S. L., Åneman, A., & Perner, A. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05754-3 · Cited by 37
“Four additional studies were included in the meta-analysis (two studies [20, 21] were found during hand-searching and another two [22, 23] following the updated database search on 20th December 2018) resulting in 55 trials being included in total.”
BackgroundSepsis in children: federal clinical guideline (draft)
Lekmanov, A. U. (2021) · Russian Journal of Pediatric Surgery Anesthesia and Intensive Care · doi:10.17816/psaic969 · Cited by 44
Use of glucocorticoids in the critical care setting: Science and clinical evidence
Chan, E. D., Chan, M. M., Chan, M. M., & Marik, P. E. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107428 · Cited by 39
Wang, G., Ma, F., Xie, K., Li, X., Tan, X., Xia, Y., Xia, Y., & Dong, J. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111335 · Cited by 35
S3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge – Update 2025
Brunkhorst, F. M., Adamzik, M., Axer, H., Bauer, M. W., Bode, C., Bone, H.-G., Brenner, T., Bucher, M., David, S., Dietrich, M., et al. (2025) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-025-01317-1 · Cited by 47
The “cytokine storm” in infection and sepsis: win the battle but lose the war
Fan, J., Li, Q.-Y., Feng, X.-F., Huang, S., Wang, R., Liao, F.-Y., Liu, D., Liu, W.-Y., Sun, J.-H., Zhang, H.-C., et al. (2026) · Military Medical Research · doi:10.1186/s40779-025-00678-0 · Cited by 52
“Combination therapy with hydrocortisone and fludro-cortisone has shown additional benefit in some trials, but other studies have failed to consistently reproduce these results [141, 142].”
Wang, H., He, C., Liu, Y., Zhao, H., Long, L., Gai, X., & Zhao, H. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110343 · Cited by 37
Immune Modulation in Sepsis, ARDS, and Covid-19 — The Road Traveled and the Road Ahead
Leligdowicz, A., Harhay, M. O., & Calfee, C. S. (2022) · NEJM Evidence · doi:10.1056/evidra2200118 · Cited by 41
Clinical trial design for unmet clinical needs: a spotlight on sepsis
Vincent, J., & Sakr, Y. L. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1643235 · Cited by 37
Predictors of dysrhythmias with norepinephrine use in septic shock
Wieruszewski, E. D., Jones, G. M., Samarin, M. J., & Kimmons, L. A. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.10.023 · Cited by 34
Guinot, P., Martin, A., Berthoud, V., Voizeux, P., Bartamian, L., Santangelo, E., Bouhemad, B., & Nguyen, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10143164 · Cited by 38
“Mineralocorticosteroids [39,72] Duration Negative No”
The Mineralocorticoid Receptor in the Vasculature: Friend or Foe?
Ibarrola, J., & Jaffe, I. Z. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042022-015223 · Cited by 35
Sepsis in the critically ill patient: current and emerging management strategies
Heming, N., Azabou, É., Cazaumayou, X., Moine, P., & Annane, D. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1846522 · Cited by 36
“hydrocortisone associated with the enteral administration of 50 μg a day of fludrocortisone over 7 days to placebo [57].”
BackgroundSelf-citationLi, J., Liu, L., Zhou, X., Lu, X., Liu, X., Li, G., & Long, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.590652 · Cited by 33
Insights Into Thiamine Supplementation in Patients With Septic Shock
Costa, N. A., Pereira, A. G., Sugizaki, C. S. D. A., Vieira, N. M., Garcia, L. R., de Paiva, S. A. R., Zornoff, L. A. M., Azevedo, P. S., Polegato, B. F., & Minicucci, M. F. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.805199 · Cited by 32
“It is important to note that hydrocortisone monotherapy in patients with septic shock is associated with faster resolution of shock (70) and lower mortality (71) when compared with placebo groups.”
BackgroundEllouze, M., Vigouroux, L., Tchérakian, C., Woerther, P., Guguin, A., Robert, O., Surénaud, M., Tran, T., Calmette, J., Barbin, T., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201948278 · Cited by 36
Self-citationTilouche, N., Jaoued, O., Ali, H. B. S., Gharbi, R., Hassen, M. F., & Elatrous, S. (2019) · Shock · doi:10.1097/shk.0000000000001316 · Cited by 33
“In the APROCCHSS study (20), the occurrence of adverse events at day 180 was lower with hydrocortisone bolus compared to the placebo group (53% vs.”
BackgroundResultInfluentialLazzaro, A., Girolamo, G. D., Filippi, V., Innocenti, G. P., Santinelli, L., Ceccarelli, G., Trecarichi, E. M., Torti, C., Mastroianni, C. M., d’Ettorre, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020803 · Cited by 38
Gómez, H., Rio‐Pertuz, G. D., Priyanka, P., Manrique-Caballero, C. L., Chang, C.-C. H., Wang, S., Liu, Q., Zuckerbraun, B. S., Murugan, R., Angus, D. C., et al. (2022) · Critical Care Medicine · doi:10.1097/ccm.0000000000005468 · Cited by 34
Roles of ginsenosides in sepsis
Yu, T., Tang, Y., Zhang, F., & Zhang, L. (2022) · Journal of Ginseng Research · doi:10.1016/j.jgr.2022.05.004 · Cited by 32
“In 2018, two clinical trials, both published in the New England Journal of Medicine, reported contrary findings on the efficacy of GCs in reducing sepsis-related death [36,37].”
Backgroundvon Groote, T., & Meersch, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195782 · Cited by 35
Metadata
- Authors
- Annane, D., Renault, A., Brun-Buisson, C., Megarbane, B., Quenot, J.-P., Siami, S., Cariou, A., Forceville, X., Schwebel, C., Martin, C., Timsit, J.-F., Misset, B., Ali Benali, M., Colin, G., Souweine, B., Asehnoune, K., Mercier, E., Chimot, L., Charpentier, C., François, B., Boulain, T., Petitpas, F., Constantin, J.-M., Dhonneur, G., Baudin, F., Combes, A., Bohé, J., Loriferne, J.-F., Amathieu, R., Cook, F., Slama, M., Leroy, O., Capellier, G., Dargent, A., Hissem, T., Maxime, V., & Bellissant, E.
- Affiliations
- Inserm (FR)
- From Service de Médecine Intensive et Réanimation, Hôpital Raymond Poincaré, Garches (D.A., V.M.), Laboratory of Infection and Inflammation Unité 1173, University of Versailles Saint-Quentin-en-Yvelines, INSERM, Montigny-le-Bretonneux (D.A.), Service de Pharmacologie Clinique–Centre d’Investigation Clinique (CIC) INSERM 1414, Centre Hospitalier Universitaire (CHU) de Rennes–Université de Rennes 1, Hôpital Pontchaillou, Rennes (A.R., E.B.), Service de Réanimation Médicale (C.B.-B.) and Service...
- ORCID
- Annane, Djillali
- Renault, Alain
- Quenot, Jean-Pierre
- Siami, Shidasp
- Cariou, Alain
- Forceville, Xavier
- Schwebel, Carole
- Misset, Benoît
- Souweine, Bertrand
- Asehnoune, Karim
- François, Bruno
- Boulain, Thierry
- Constantin, Jean-Michel
- Combes, Alain
- Bohé, Julien
- Amathieu, Roland
- Cook, Fabrice
- Slama, Michel
- Capellier, Gilles
- Dargent, Auguste
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03
- Volume
- 378
- Issue
- 9
- Pages
- 809-818
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2794125559
- Cited by
- 939
- References
- 22
- Citations by year
- 2026: 107 · 2025: 104 · 2024: 97 · 2023: 115 · 2022: 101 · 2021: 98 · 2020: 121 · 2019: 123 · 2018: 70
- FWCI
- 80.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Funders
- Ministère des Affaires Sociales et de la Santé (Programme Hospitalier de Recherche Clinique / P 07)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- cortisol, fludrocortisone, drotrecogin alfa (activated), corticosteroid therapy, host response to infection, 90-day mortality, vasopressor-free days, organ failure, mechanical ventilation, intensive care unit discharge, sepsis treatment
- MeSH terms
- Simplified Acute Physiology Score, Aged, Anti-Inflammatory Agents, Cause of Death, Combined Modality Therapy, Double-Blind Method, Drug Therapy, Combination, Female, Fludrocortisone, Humans, Hydrocortisone, Male, Middle Aged, Recurrence, Respiration, Artificial, Shock, Septic, Survival Analysis, Treatment Outcome, Renal Replacement Therapy, Organ Dysfunction Scores
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.